Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

October 1, 2026 9:45 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $920.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments